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Abstract
Background: Tuberculosis (TB) is a major cause of mortality and suffering worldwide, with over 95% of TB deaths
occurring in low- and middle-income countries. In recent years, molecular typing methods have been widely used
in epidemiological studies to aid the control of TB, but this usage has not been the case with many African
countries, including Cameroon. The aims of the present investigation were to identify and evaluate the diversity of
the Mycobacterium tuberculosis complex (MTBC) isolates circulating in two ecological zones of Cameroon, seven
years after the last studies in the West Region, and after the re-organization of the National TB Control Program
(NTBCP). These were expected to shed light also on the transmission of TB in the country. The study was
conducted from February to July 2009. During this period, 169 patients with symptomatic disease and with sputum
cultures that were positive for MTBC were randomly selected for the study from amongst 964 suspected patients in
the savannah mosaic zone (West and North West regions) and the tropical rainforest zone (Central region). After
culture and diagnosis, DNA was extracted from each of the MTBC isolates and transported to the BecA-ILRI Hub in
Nairobi, Kenya for molecular analysis.
Methods: Genetic characterization was done by mycobacterial interspersed repetitive unit–variable number
tandem repeat typing (MIRU-VNTR) and Spoligotyping.
Results: Molecular analysis showed that all TB cases reported in this study were caused by infections with
Mycobacterium tuberculosis (98.8%) and Mycobacterium africanum (M. africanum) (1.2%) respectively. We did not detect
any M. bovis. Comparative analyses using spoligotyping revealed that the majority of isolates belong to major clades of
M. tuberculosis: Haarlem (7.6%), Latin American-Mediterranean (34.4%) and T clade (26.7%); the remaining isolates
(31.3%) where distributed among the minor clades. The predominant group of isolates (34.4%) corresponded to
spoligotype 61, previously described as the “Cameroon family. Further analysis based on MIRU-VNTR profiles had
greater resolving power than spoligotyping and defined additional genotypes in the same spoligotype cluster.
Conclusion: The molecular characterization of MTBC strains from humans in two ecological regions of Cameroon has
shown that M. tuberculosis sensu stricto is the predominant agent of TB cases in the zones. Three decades ago, TB was
reported to be caused by M. africanum in 56.0% of cases. The present findings are consistent with a major shift in the
prevalence of M. tuberculosis in Cameroon.
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Background
Tuberculosis (TB) represents one of the most challen-
ging threats to global human health. M. tuberculosis
causes about 8.8 million new cases of active tuberculosis
and 1.1 million deaths annually [1]. Moreover, it is esti-
mated that over one-third of the world population has
latent tuberculosis infection, which represents a huge res-
ervoir for the disease. Exponential development of travel
extends this threat worldwide [1]. Ninety-five percent of
cases occur in developing countries, where the lack of
proper health care systems leads to incomplete case detec-
tion and treatment. The high prevalence of HIV, which
weakens the immune system, favours the spread of latent
TB infection .The emergence and spread of resistance to
first line TB drugs has rendered the control of the disease
more difficult in sub-Saharan Africa [2].
In Cameroon, a country with 18 million inhabitants,
the incidence rate of TB is estimated to have increased
from 77 cases per 100,000 inhabitants in 2000 to 91
cases per 100,000 inhabitants in 2004 [3]. In 2007,
about 43% of all new cases were shown to occur in
HIV positive individuals. According to the National
TB Control Programme (NTBCP) in 2008, 25,125
new sputum smear-positive cases were reported.
Despite the implementation of the directly observed
treatment short course strategy (DOTs) the incidence
is still increasing [4]. One study performed 30 years
ago reported that 56% of cases of TB were due to
M. africanum strains in the West and South regions
of Cameroon [5]. Another study in the West region
of Cameroon showed that 42% of the M. tuberculosis
strains collected between July 1997 and June 1998
belonged to one highly genetically-related group of
strains designated the “Cameroon family” [4].
Several intervention strategies are expected to reduce
the incidence of TB. In recent years, molecular typing
methods have become useful tools in epidemiological
studies for the control of TB, and have revealed insights
into the population structure of clinical isolates in different
geographical locations. Two of the most useful typing
methods are spoligotyping [6] based on polymerase
chain reaction (PCR) amplification of a highly polymorphic
direct repeat locus in the M. tuberculosis genome, and
mycobacterial interspersed repetitive-unit–variable-num-
ber tandem-repeat (MIRU-VNTR) [7], which uses length
polymorphisms of minisatellite-like loci in the genome.
Spoligotyping targeting the direct repeat locus is a
rapid, simple, and cost-effective system that allows
the simultaneous detection and differentiation of M.
tuberculosis complex (MTBC) strains and provides
genotypic information [6]. It is a good indicator of
strain identity and provides information about epide-
miologically important clones [8]. Another advantage
of spoligotyping is its ability to measure the overall
diversity of M. tuberculosis complex strain patterns,
including differences between regions and popula-
tions and the prevalence of endemic strains [9,10].
MIRU-VNTR typing is technically flexible, as sizing
can be done using capillary [11,12] or gel electrophoresis
[13] or non denaturing high-performance liquid chro-
matography [14]. It is one of the most promising
PCR-based method for detecting the number of tan-
dem repeats at a given genetic locus. Supply et al.
[15] defined a set of 15 MIRU-VNTR loci for mo-
lecular epidemiological investigations and a set of 24
MIRU-VNTR loci for phylogenetic analysis of M.
tuberculosis strains worldwide. In support of this, an-
other study concluded that this “real-time” MIRU-
VNTR genotyping approach was highly applicable
for population based studies [16]. This view was
reinforced by a study conducted in the Brussels re-
gion, where the authors concluded that a standardized
MIRU-VNTR genotyping method could be a new refer-
ence for epidemiological and phylogenetic screening of M.
tuberculosis strains because it is useful to confirm
spoligotyping clusters or to discriminate among the isolates
that they contain [17].
The aims of the present study were to identify and
evaluate the diversity of the M. tuberculosis complex
isolates using spoligotyping and MIRU-VNTR in the
savannah mosaic zone (West and North West regions)
and the tropical rainforest zone (Central region) in
Cameroon, seven years after the last studies in the
West Region and after the re-organisation of the
National TB Control Programme (NTBCP). These
were expected to shed light also on the transmission
of TB in the country since the last studies.
Methods
Study population and classification of samples
The study was conducted from February to July 2009 and
among 964 subjects 169 patients presented positive cul-
ture for MTBC. Seventy-one of these patients came from
three centers for detection of TB (CDT) of the rainforest
zone (Jamot Hospital, Mbalmayo District Hospital and
Catholic Health Center of Mvolyé), 98 patients came from
three CDT of the Savannah mosaic zone (Regional Hos-
pital of Bafoussam, District Hospital of Baleng and District
Hospital of Djeleng, Bamenda Regional Hospital). Sputum
samples that were positive by microscopy from the Centre
and West Regions were kept at +4°C and transported
twice weekly to the Mycobacterium Laboratory of the
Centre Pasteur du Cameroun in Yaoundé for bacterio-
logical analysis. Samples from North-West Region were
transported twice weekly to the Mycobacterium Labora-
tory of the University of Buea located at the Regional Hos-
pital of Buea for bacteriological analysis.
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Ethical considerations
Ethical clearance No. 112/CNE/SE/09 was obtained from
the Cameroon National Ethics Committee in Yaoundé.
For inclusion in the study patients had to be aged
15 years and above, presenting with clinical symptoms
of tuberculosis, and had to sign or thumbprint a written
patient consent form.
Bacteriological analysis
Each sputum sample was retested for acid-fast-bacilli
(AFB) by the Ziehl Neelsen method [17], and then cultured
in three Lőwenstein-Jensen (LJ) tubes, one of which was
supplemented with a 0.4% solution of sodium pyruvate.
The cultures were incubated at 37°C and examined weekly
for growth for up to 10 weeks. Strain identification was
based on the following criteria: growth rate, colony
morphology, growth affinity for pyruvate, niacin produc-
tion, reduction of nitrates and catalase activity.
Drug susceptibility testing was performed using the
indirect proportion method on LJ medium as described
by Canetti et al. [18]. The following anti-tuberculosis
drugs were tested: Rifampicin (R) 40 mg/l, isoniazid (H1)
0.1 mg/l, Isoniazid (H2) 0.2 mg/l, streptomycin (S) 4 mg/l,
and ethambutol (E) 2 mg/l. An isolate was considered
resistant to a particular antibiotic if the number of col-
onies on the drug-containing medium was 1% or more of
the number on the drug-free medium.
DNA extraction
The DNA from clinical MTBC isolates was extracted
using a standard protocol [19]. In brief, a minimum of
four bacterial colonies was transferred to 200 μl Tris-
EDTA buffer, pH 8, and heated for 15 min for 95°C. Fifty
μl of lysozyme (20 mg/ml) was then added to each tube,
followed by incubation overnight at 37°C. One hundred μl
of SDS/proteinase K solution (containing 10 μl 20 mg/ml
proteinase K and 90 μl 10% SDS), were then added and
the tubes were vortexed gently and incubated for 10 min
at 65°C. One hundred μl CTAB/NaCl solution (10%w/v
CTAB [N-cetyl-N,N, N,-trimethylammoniumbromide]
and 4.1% w/v NaCl in distilled water) was added, followed
immediately by the addition of 100 μl 5 M NaCl. The
tubes were then vortexed and incubated for 10 min at
65°C. Seven hundred and fifty μl of chloroform-isoamyl
alcohol (24:1) was added to each tube, and the tubes were
vortexed and centrifuged at 12,000 g for 5 min at
room temperature. The genomic DNA present in the
resulting aqueous phase was precipitated with ethanol
and redissolved in 50 μl of Tris-EDTA buffer, pH 8.
Spoligotyping
All isolates were analyzed by spoligotyping as described
previously [6]. In brief, biotin-labelled PCR products from
the amplification of the direct-repeat locus were hybridized
against an array of 43 direct-repeat spacer oligonucleotides
in a Miniblotter MN45 (Ocimum Biosolutions). The resul-
ting hybridization signals were revealed by chemilumines-
cence and were visualized as profiles of discrete spots.
Each spoligotype pattern was classified into a binary code.
The data obtained were compared with the international
SpolDB4.0 database, containing 35,925 spoligotypes from
122 countries [6].
MIRU-VNTR genotyping
MIRU-VNTR analysis was performed with 24 published
markers, and loci were PCR amplified as described pre-
viously [20], except that PCRs were done in single re-
actions and not multiplexed. In brief, PCR mixtures
were prepared as follows: DNA (1 μl) was added to 9 μl
PCR master mix containing 0.04 μl (0.4 U) of HotStarTaq
Table 1 Clinically suspected cases of tuberculosis for selected locations in Cameroon, and incidence of positive
sputum smears




Tropical rainforest zone Central Jamot Hospital 75 39 (52%)
District Hospital of Mbalmayo 125 27 (21.6%)
Catholic health Centre of Mvolyé 113 09 (7.9%)
Subtotal 309 71 (23.9%)
Savannah mosaic zone West District Hospital of Djeleng 130 35 (26.9%)
Regional Hospital of Bafoussam 209 22 (10.5%)
District Hospital of Baleng 104 22 (21.1%)
North-West Regional Hospital of Bamenda 220 27 (12.2%)
Subtotal 655 98 (14.9%)
Total 964 169 (17.5%)
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DNA polymerase (Qiagen), 2 μl of Q-solution (Qiagen),
0.2 mM each of dATP, dCTP, dGTP, and dTTP (Qiagen),
1 μl of HotStarTaq 10 x PCR buffer, 1.5 to 3.0 mM MgCl2,
0.4 μM of unlabeled oligonucleotide and 0.04 to 0.4 μM
of dye-labeled oligonucleotide (Applied Biosystems).
Negative controls consisted of PCRs without template
DNA. For positive controls PCRs were performed
with DNA from reference strains M. tuberculosis
H37Rv and Mycobacterium bovis (M. bovis) BCG P3
(Ocimum Biosolutions). The thermocycling condi-
tions were identical for all 24 loci: 15 min at 95°C,
followed by 40 cycles of 1 min at 94°C, 1 min at 59°
C, and 1 min 30 s at 72°C, followed by a final step
of 10 min at 72°C. PCR products were mixed with
GeneScan 1200 LIZ Size Standard (Applied
Biosystems) and analyzed on 3730 or 3130 Genetic
Figure 1 Spoligotype patterns of the 71 strains investigated in the Centre Region of Cameroon.
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Analyzers (Applied Biosystems). Sizing of the PCR
fragments and assignment of the various VNTR al-
leles were performed using customized GeneMapper
software (Applied Biosystems).
Statistical analysis
The individual spoligotype patterns were compared
with an updated in-house proprietary version of the
SpolDB4 database at the Institut Pasteur de Guadeloupe,
named SITVIT2 (http://www.pasteurguadeloupe.fr:8081/
SITVITDemo). The allelic diversity at a given VNTR locus
was calculated and generated automatically as described
previously [21]. The MIRU-VNTRplus service (www.
miru-vntrplus.org) was used to compare the MIRU-
VNTR and spoligotyping profiles obtained in this study
with reference strains for the assignment of MTBC
species, lineages, and genotypes. The clustering rate
was defined as described previously [21]. A strain clus-
ter was defined as two or more patients infected by
strains having identical spoligotypes and MIRU-VNTR
patterns.
Results
The study was conducted from February 21 to July
2009 of pulmonary TB that were culture positive for
the MTBC were randomly selected for the study
amongst 964 subjects who presented clinical symptoms
of tuberculosis at the hospital study sites in the
savannah mosaic zone (West and North West regions)
and the tropical rainforest zone (Central region)
(Table 1). The age of patients ranged from 15 to
75 years (mean age, 34 years). The female-to-male sex
ratio was 1:3, with similar distribution in both
ecological zones studied.
Identification and genotyping of M. tuberculosis strains
The spoligotyping method employed for genotyping of
MTBC assigned 167 of the isolates to M. tuberculosis
and 2 isolates to M. africanum out of a total of 169
cases tested.
In the tropical rainforest zone (Centre Region), 71
isolates were subjected to spoligotyping, 17 discrete
spoligotypes of M. tuberculosis were detected (Figure 1).
A total of 59 (83%) isolates were grouped into five clusters
(LAM10_CAM, Haarlem, T1, Uganda I, T2) whereas
12 (17%) presented a single spoligotype each. The 17
Spoligotypes were compared with those contained in the
international spoligotyping database (SpolDB4) and it was
found that 61 isolates were already described in SpolDB4
while 10 were new or unique. (C3, C29, C32, C55, C74,
C99, C115, C134, C137, C154) (Table 2). The largest clus-
ter consisted of 24 (34%) strains belonging to the Latin
American-Mediterranean (LAM) family and exclusively to
the one called LAM10_CAM type, 20 strains
Table 2 Allelic diversity of the 24 MIRU-VNTR loci
Allelic diversity
Locus Centre West North-West
154(MIRU 2) 0.01 0.04 0.04
424(Mtub 04) 0.24 0.41 0.22
577(ETRC) 0.57 0.59 0.28
580(MIRU 04) 0.14 0.17 0.1
802(MIRU 40) 0.74 0.71 0.69
960(MIRU 10) 0.54 0.45 0.46
1644(MIRU 16) 0.54 0.65 0.52
1955(Mtub 21) 0.59 0.37 0.39
2059 (MIRU 20) 0.62 0.56 0.66
2163b (QUB 11b) 0.74 0.73 0.63
2165(ETRA) 0.56 0.63 0.47
2347(Mtub 29) 0.47 0.51 0.56
2401(Mtub 30) 0.46 0.48 0.38
2461(ETRB) 0.71 0.71 0.51
2531(MIRU 23) 0.14 0.14 0.28
2687(MIRU 24) 0.44 0.47 0.51
2996(MIRU 26) 0.56 0.36 0.42
3007(MIRU 27) 0.56 0.57 0.65
3171(Mtub 34) 0.28 0.14 0.16
3192(MIRU 31) 0.17 0.38 0.16
3690(Mtub 39) 0.51 0.63 0.75
4052(QUB 26) 0.68 0.67 0.73
4156(QUB 4156) 0.65 0.58 0.57
4348(MIRU 39) 0.14 0.14 0.16
Table 3 Relative prevalence (in%) of MTBC Spoligotypes








LAM10_CAM 33.8 30.9 37.0 33.9
Haarlem 3 11.2 4.2 3.7 6.4
T1 23.9 26.7 25.9 26.7
Uganda I 8.4 1.4 3.7 4.5
West African 1 0 1.4 0 0.4
West African 3 0 0 3.7 1.2
Orphan 14.1 22.5 14.8 17.1
T2 5.6 4.2 3.7 4.5
LAM1 0 2.8 0 0.93
T5 1.4 2.8 0 1.4
TUR 0 0 3.7 1.2
Haarlem 1 1.4 5.6 3.7 3.5
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corresponding to spoligotype 61 (Cameroon family), 2
strains (ST 847), one single strain (ST 838) and another
single strain (ST852). This cluster is followed by the ubi-
quitous T1 spoligotype for a total of 17 (23%), 12 desig-
nated in the SpolDB4 database as spoligotype 53
(Ghana strains), 3 as spoligotype 1166 and 2 as
spoligotype 1475. Three other important clusters (18
strains) were found, one cluster with 8 (11%) strains
belonged to the ubiquitous Haarlem family,
spoligotype 50, another with 6 (8%) strains belonged to
Uganda I strains with spoligotypes 450 (3 strains), 237
(2 strains) and 46 (one strain), the third cluster
belonged to the ubiquitous T2 spoligotype for a total
of 4 (6%) with spoligotype 848, 1056 and 853, one sin-
gle strain is designated in the SpolDB4 database as
spoligotype 44 (also known as the T5 family) and an-
other as spoligotype 47 called H1 family (Table 3). The
clustering rate of the spoligotyping was 0.62.
In the savannah mosaic zone (West region and North-
West region), spoligotyping showed that 25 patterns
were detected among the 98 isolates. A total of 73 (74.4%)
isolates were grouped into 7 clusters (LAM10_CAM,
Haarlem3, T1, T2, T5, LAM1, Haarlem1), whereas 25
(25.6%) presented a single spoligotype. The 98 isolates
were compared with those contained in the inter-
national spoligotyping database (SpolDB4). A total of
Figure 2 Spoligotype patterns of the 71 strains investigated in the West Region of Cameroon.
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78 isolates were already described in SpolDB4 while 20
were new and unique (W4, W5, W19, W25, W33, W34,
W39, W42, W84, W85, W93, W95, W104, W105 W143,
W147, NW 23, NW 38, NW 20, NW 16) (Table 3)
and (Figures 2 and 3). Table 3 summarizes the distribu-
tion of the spoligotypes identified in the present investi-
gation. It can be seen that the largest cluster of 33
(33.6%) belonged to the Latin American-Mediterranean
(LAM) family and exclusively to the type called
LAM10_CAM. Other prominent strains included the
Cameroon family (spoligotype ST 61), the Ghanian and
Harlem spoligotypes. One single strain is designated in the
SpolDB4 database as spoligotype 450 called Uganda I
family and another as spoligotype 332 called West
African 1 family (Table 3). The clustering rate of the
spoligotyping was 0.52.
MIRU-VNTR analysis was performed in both eco-
logical zones on all the 169M. tuberculosis isolates
by using 24 published markers [13], which included
12 MIRU, 3 ETR, 7 QUB and 2 VNTR loci. The 169
isolates were all distributed into unique patterns
(100%). The clustering rate of the MIRU-VNTR was
0.014 for the tropical rainforest zone and 0 for the
savannah mosaic zone. The allelic diversity (h) dif-
fered for the individual loci, ranging from 0.01 to
0.75 for all zones investigated. The MIRU40, QUB
26 and QUB11b loci showed the highest discrimin-
atory power (h = 0.74), ETRB, QUB26, QUB4156 also
showed the high allelic diversity (h = 0.6 - 0.68), and
five other loci (MIRU 2, MIRU4, MIRU 23, MIRU31,
and MIRU39, Mtub 34) showed low discriminating
power (h < 0.2). The other supplemental locus had a
relatively high allelic diversity (0.2 < h <0.6) (Table 2).
The combination of the spoligotyping and MIRU-VNTR
data revealed a further resolution of some of the clustered
isolates identified by spoligotyping alone. (Figures 4, 5
and 6).
As earlier reported, both resistance to single first
line drugs and multidrug resistance phenotypes were
detected in all the ecological zones studied [22],
the resistance profile compared with types of
spoligotypes in the tropical rainforest zone revealed
a resistance of 21% to INH. 15.7% to RIF and 15.7%
to SM for LAM10_CAM (ST 61). For the same
spoligotype we obtained an MDR rate of 15.7% and
5.26% for monoresistances. For the Ghanaian family,
16.6% were MDR and 8.3% were resistant to at least
one drug. In the Savannah mosaic zone for the
LAM10_CAM, 8.3% were resistant to INH and 4.1%
to SM. For the Harlem3, 12.5% were resistant to RIF,
50% were resistant to RIF for the Uganda family,
20% of the T1 family was resistant to SM, 50% of
the T2 family was resistant to both INH and RIF,
only one new spoligotype presents resistant to INH.
When these prevalence rates of the spoligotypes
were compared with the phenotype result no signifi-
cant correlations were observed. Also A comparative
analysis of the 2 ecological zones did not show any
correlations between the ecological zone and the dis-
tribution of spoligotypes (Table 4).
Figure 3 Spoligotype patterns of the 27 strains investigated in the North-West Region of Cameroon.
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Discussion
The main aims of the present investigation were to
determine the etiologic agent of tuberculosis and its
genetic diversity in Cameroon, 7 years after it was
first identified and during which a national anti-
tuberculosis programme had been instituted. In this
study we show that M. tuberculosis sensu stricto is
the main cause of tuberculosis among patients in two
ecological zones covering three administrative regions
of Cameroon.
Of the samples tested Spoligotyping and MIRU-VNTR
identified 167 strains (98.8%) of M. tuberculosis and two
strains (01.2%) of M. africanum. In the 1970s, most
reported cases of TB in Cameroon were caused by M.
africanum [5]. Our results indicate a shift in type of
infectious agent M. tuberculosis versus M. africanum in
Cameroon. A similar study conducted by Niobe-
Eyangoh et al. [4] suggested that the decreasing trend
observed cannot be attributed to identification bias, but
probably reflects a genuine regression of M. africanum
(from 56 to 9%) as the etiologic agent of TB in Cameroon
during the last 3 decades. Studies by Simonet et al. [23]
and Ledru et al. [24] also showed a decrease of M.
africanum responsible for human tuberculosis cases in
Figure 4 Spoligotype and 24 loci MIRU-VNTR typing patterns of the 71 strains investigated in the Centre Region of Cameroon.
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Burkina Faso. However, the factors that contribute to the
reduction of this species have not been unraveled. Con-
ceivably, the implementation of the Direct Observed
Treatment strategy (DOTs) in Cameroon and
our use of more sensitive and specific genotyping
methods could account at least in part for the differ-
ences observed.
The molecular investigation of the Cameroonian
strains by spoligotyping did not show the specific
signature of M. bovis despite the high prevalence of
bovine TB among cattle [25]. This result is in agree-
ment with published findings in Cameroon and
Burkina-Faso showing the absence of, or an ex-
tremely low prevalence of, bovine TB among humans
[4,24,26]. The low rate of human pulmonary TB
caused by M. bovis in our study could be explained
by different factors: (i) a high number of the M.
bovis infections are responsible for extrapulmonary
TB cases and in our study the TB cases were essentially
pulmonary cases or (ii) pulmonary TB due to M. bovis
may be more frequent in rural areas [26]. However, the
majority of the patients in our study were from urban
areas (Yaounde, Mbalmayo, Bafoussam, and Bamenda).
The comparison of spoligotyping from the 2 ecological
zones investigated with the International Spoligotyping
database showed that the three major clusters belong to
major clades of M. tuberculosis (LAM10_CAM: 34%;
and T1: 27%; Haarlem: 7%), the remaining isolates
(32%) where distributed among the minor clades.
This study demonstrated that LAM10_CAM is a
dominant strain just as was the case in Tanzania
[27]. However, in Harare and Zimbabwe [27],
LAM11 was predominant indicating that the preva-
lence rates of various LAM sub-families might vary
Figure 5 Spoligotype and 24 loci MIRU-VNTR typing patterns of the 71 strains investigated in the West Region of Cameroon.
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among different region of Africa, and that TB and
that TB epidemics might be diverse and localized.
The success of the LAM family in particular in this
community is intriguing and needs to be followed up
in larger population-based studies.
Although spoligotyping suggested some clustering of
isolates (Table 3) further analysis using the MIRU-
VNTR resolved the apparent clusters into distinct geno-
types. This is not surprising considering the high dis-
criminating power of the latter method. It is therefore
recommended, that wherever possible, both methods
should be employed to give a clearer picture of the gen-
etic diversity. Although a previous study in Yaoundé [28]
had suggested a preponderance of drug resistant pheno-
types among the LAM10_ CAM family, we found no
such correlations in the present study.
The clustering rate obtained from the two methods
used was very different: 0.52 to 0.62 for the spoligotying
and 0 for the MIRU-VNTR. This discrepancy is
probably attributable to the small size of the conveni-
ence sample employed. A population based study with
a larger randomly selected sample is indicated to
determine the status of TB transmission in the
studied area.
Conclusions
Our investigation of genetic polymorphism of M.
tuberculosis complex strains from humans in two
ecological regions of Cameroon has shown M. tuber-
culosis sensu stricto to be the predominant agent of
TB cases, with the preponderance of the LAM10
family genotype. Further studies to monitor the evo-
lution of the dominant genotypes in the country and
region are indicated as essential to the ongoing anti-
TB campaign.
Table 4 Comparative analysis of the 2 ecological zones
Distribution of
the sample collected
Tropical rain forest zone Savannah mosaic zone P-value
(Central region) (West and North West regions)
Number of clinically suspected cases 309 655 /
Number of positive sputum smears 71 98 0.0022
Relative prevalence
of MTBC Spoligotypes
LAM10_CAM 24 33 0.98
Haarlem 3 8 5 0.137
T1 17 23 0.94
Uganda I 6 4 0.324
Orphan 10 20 0.282
Figure 6 Spoligotype and 24 loci MIRU-VNTR typing patterns of the 27 strains investigated in the North-West Region of Cameroon.
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